Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis

INTRODUCTION: Outcomes of immune checkpoint inhibitor (ICI) rechallenge in NSCLC remain uncertain. This study estimated the safety and efficacy of ICI rechallenge and compared rechallenge benefit among different reasons of initial ICI discontinuation in NSCLC. METHODS: PubMed, EMBASE, and Cochrane L...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Shiting, Shukuya, Takehito, Tamura, Jun, Shimamura, Shoko, Kurokawa, Kana, Miura, Keita, Miyawaki, Taichi, Hayakawa, Daisuke, Asao, Tetsuhiko, Yamamoto, Kouji, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011115/
https://www.ncbi.nlm.nih.gov/pubmed/35434666
http://dx.doi.org/10.1016/j.jtocrr.2022.100309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011115/
https://www.ncbi.nlm.nih.gov/pubmed/35434666
http://dx.doi.org/10.1016/j.jtocrr.2022.100309

Ejemplares similares